11:19 AM EDT, 09/10/2025 (MT Newswires) -- Ardent Health's ( ARDT ) core commercially insured and Medicare patient populations will continue to enhance earnings over the coming years, UBS said in a Wednesday note.

The company has a "solid' portfolio of acute care hospitals, having "ample" opportunity to continue expanding its core commercial and Medicare services, analysts led by AJ Rice wrote.

Additionally, the analysts said that the reconciliation bill on July 4 eliminated a "significant" source of uncertainty for Ardent, and although the legislation will affect the firm's future earnings, the analysis of every provision demonstrates that the challenges will "ultimately" be manageable.

Ardent's medium-term earnings trajectory also looks solid due to the New Mexico directed payment program's approval, the analysts mentioned.

UBS initiated Ardent Health's ( ARDT ) coverage with a buy rating and a $17 price target.

Shares of the company were down over 2% in recent Wednesday trading.

Price: 13.22, Change: -0.26, Percent Change: -1.93